Since 2004 the Resource Tracking for HIV Prevention Research and Development Working Group (“Working Group”) has employed a comprehensive methodology to track trends in research and development (R&D) investments and expenditures for biomedical AIDS prevention options, including:
- AIDS vaccines
- Pre-exposure prophylaxis (PrEP)
- Treatment as prevention (TasP)
- Voluntary medical male circumcision (VMMC)
- Female condoms
- Prevention of vertical transmission (PMTCT)
AVAC also collaborates with the International AIDS Society (IAS) to estimate global investments in HIV cure research, which also includes therapeutic HIV vaccines. The latest report, Global Investment in HIV Cure Research and Development in 2018 is available.
Click on the links for more information.